P312: Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate–severe ulcerative colitis: UNIFI
ECCO '19 Copenhagen
2019
P313: Impact of upadacitinib on the general clinical condition of patients with Crohn’s disease (CD): data from the randomised CELEST study
ECCO '19 Copenhagen
2019
P315: Systemic and tissue modulation of IL-23 pathway biomarkers in a Phase 2 study of risankizumab in patients with Crohn’s disease
ECCO '19 Copenhagen
2019
P316: Transanal minimal invasive proctectomy (TaMIP) for perineal Crohn’s disease; a multi-centre prospective cohort study
ECCO '19 Copenhagen
2019
P317: Characterisation of patients with delayed response to ustekinumab for Crohn’s disease
ECCO '19 Copenhagen
2019
P318: Ustekinumab: early experience and medium-term outcomes from a UK multi-centre real-world cohort
ECCO '19 Copenhagen
2019
P319: Trough levels of adalimumab better correlate with combined mucosal and transmural healing than clinical remission in Korean patients with Crohn’s disease on adalimumab maintenance therapy
ECCO '19 Copenhagen
2019
P320: High Cytomegalovirus DNA load in mucosal biopsies predicts steroid failure as well as colectomy in acute severe ulcerative colitis
ECCO '19 Copenhagen
2019
P321: On effectiveness, safety, and TDM of thioguanine in a cohort of 274 patients with IBD, intolerant for conventional thiopurines
ECCO '19 Copenhagen
2019
P322: Disease-related worries and concerns in patients with ulcerative colitis: 1-year data from ICONIC
ECCO '19 Copenhagen
2019
P324: Tuberculosis infection under anti-TNF therapy – should we be looking for it?
ECCO '19 Copenhagen
2019
P325: Integrating efficacy and safety of vedolizumab and other advanced therapies for the treatment of ulcerative colitis: Results from a network meta-analysis
ECCO '19 Copenhagen
2019
P326: Audit and review of infliximab therapeutic drug monitoring and prescribing practices in paediatric inflammatory bowel disease (IBD) patients
ECCO '19 Copenhagen
2019
P327: Segmental colectomy for ulcerative colitis: a new paradigm? A multi-centric study in 72 patients
ECCO '19 Copenhagen
2019
P328: Low vitamin K, vitamin D and calcium dietary intake in IBD patients represents a potentially reversible risk factor for osteoporosis
ECCO '19 Copenhagen
2019
P329: Adalimumab therapeutic drug monitoring test validated for measuring ABP 501 biosimilar
ECCO '19 Copenhagen
2019